NasdaqCM - Nasdaq Real Time Price USD

Psyence Biomedical Ltd. (PBM)

Compare
0.0498 -0.0027 (-5.14%)
As of 10:13 AM EST. Market Open.
Loading Chart for PBM
DELL
  • Previous Close 0.0525
  • Open 0.0509
  • Bid --
  • Ask --
  • Day's Range 0.0475 - 0.0511
  • 52 Week Range 0.0475 - 14.5500
  • Volume 27,623,323
  • Avg. Volume 6,676,574
  • Market Cap (intraday) 3.156M
  • Beta (5Y Monthly) -0.43
  • PE Ratio (TTM) --
  • EPS (TTM) -7.8200
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

www.psyencebiomed.com

--

Full Time Employees

March 31

Fiscal Year Ends

Recent News: PBM

View More

Performance Overview: PBM

Trailing total returns as of 11/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PBM
99.46%
S&P 500
23.10%

1-Year Return

PBM
99.56%
S&P 500
30.08%

3-Year Return

PBM
99.50%
S&P 500
24.61%

5-Year Return

PBM
99.50%
S&P 500
24.61%

Compare To: PBM

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PBM

View More

Valuation Measures

Annual
As of 11/19/2024
  • Market Cap

    3.33M

  • Enterprise Value

    13.04M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -126.35%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -51.16M

  • Diluted EPS (ttm)

    -7.8200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    733.19k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -1.71M

Company Insights: PBM

People Also Watch